General Publications February 1, 2019

Alston & Bird Healthcare Week in Review, February 1, 2019

Alston & Bird’s Week in Review provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and Congressional committee action; reports, studies, and analyses; and other health policy news.

I. Regulations, Notices, & Guidance

Event Notices   

  • February 20, 2019: The Health Information Technology Advisory Committee announced a public meeting. The Committee will develop recommendations for the National Coordinator on interoperability.
  • February 27, 2019: The Substance Abuse and Mental Health Services Administration (SAMHSA) announced a public meeting of the Center for Substance Abuse Treatment National Advisory Council (NAC). The NAC will discuss recovery housing and expanding access to medication-assisted treatment.
  • March 8, 2019: The FDA announced a public meeting of the Microbiology Devices Panel. The panel will discuss and make recommendations regarding new or alternative approaches to the clinical study design and evaluation of devices detecting Human Papillomavirus (HPV).
  • April 10, 2019: The FDA announced a public meeting entitled, Prescription Drug User Fee Act of 2017; Electronic Submissions and Data Standards. The purpose of the meeting is to fulfill FDA’s commitment to seek stakeholder input related to data standards and the electronic submission systems’ past performance, future targets, emerging industry needs and technology initiatives.

II. Congressional Legislation & Committee Action

U.S. Senate

  • On January 29, 2019, the Senate Committee on Health, Education, Labor, and Pensions held a hearing entitled, Access to Care: Health Centers and Providers in Underserved Communities. Witnesses included: Dennis Freeman, Ph.D., Chief Executive Officer, Cherokee Health Systems; Andrea Anderson, M.D., Director of Family Medicine, Unity Health Care; John Waits, M.D., Residency Director Cahaba Family Medicine Residency; Thomas Trompeter, President, HealthPoint.
  • On January 29, 2019, the Senate Finance Committee held a hearing entitled, Drug Pricing in America: A Prescription for Change, Part I. Witnesses included:  Kathy Sego, Mother of a Child with Insulin-Dependent Diabetes; Douglas Holtz-Eakin, Ph.D., President, American Action Forum; Mark Miller, Ph.D., Vice President of Health Care, Laura and John Arnold Foundation; and Peter Bach, M.D., Director, Memorial Sloan Kettering Center for Health Policy and Outcomes.

House of Representatives

  • On January 29, 2019, the House Ways and Means Committee held a hearing entitled, Protecting Americans with Pre-existing Conditions. Witnesses included: Karen Pollitz, Senior Fellow at the Kaiser Foundation; Andrew Stolfi, Insurance Commissioner in the Oregon Division of Finance Regulation; Keysha Brooks-Coley, Vice President for Federal Advocacy & Strategic Alliances at the American Cancer Society; Andrew Blackshear, American Heart Association; Rob Robertson, Chief Administrator/ Secretary-Treasurer for the Nebraska Farm Bureau.
  • On January 29, 2019, the House Committee on Oversight and Reform held a hearing entitled, Examining the Actions of Drug Companies in Raising Prescription Drug Prices. Witnesses included: Antoinette Worsham, Mother of Two Insulin-Dependent Daughters; Catherine Alicia Georges, Ed.D., RN, FAAN, National Volunteer President, AARP; Aaron Kesselheim, M.D., J.D., M.P.H., Associate Professor of Medicine, Program on Regulation, Therapeutics and Law, Harvard Medical School; Gerard Anderson, Ph. D., Professor of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University; and Avik Roy, M.D., President, Foundation for Research and Equal Opportunity.

III. Reports, Studies, & Analyses

IV. Other Health Policy News

  • On January 30, 2019, CMS released Part II of the 2020 Advanced Notice of Methodological Changes for Medicare Advantage Capitation Rates and Part D Payment Policies (2020 Advance Notice), and Draft Call Letter. The 2020 Advance Notice and Draft Call Letter are available here.
Media Contact
Alex Wolfe
Communications Director

This website uses cookies to improve functionality and performance. For more information, see our Privacy Statement. Additional details for California consumers can be found here.